Unfortunately, data thus far have shown limited benefit for ICI in Multiple Myeloma, suggesting that polymorphisms within the PD-1 and CTLA-4 genes may play a role in the variability of responses among all hematologic malignancies. Here, CTLA4 is linked to plasma cell myeloma.